NCT06513338View on ClinicalTrials.gov

Complement C5 mAb in the Treatment of Anti-GBM Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Autoimmune Diseases
Interventions
DRUG

Eculizumab

eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11

Trial Locations (1)

100038

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT06513338 - Complement C5 mAb in the Treatment of Anti-GBM Disease | Biotech Hunter | Biotech Hunter